Eligibility Pre-Screening

Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

This is a simplified pre-screening tool. Your answers help estimate whether you might qualify, but only the research team can confirm your eligibility. This is not medical advice.

Question 1 of 60%

1.Have you been diagnosed with clear cell renal cell carcinoma (a type of kidney cancer) that is locally advanced or metastatic (has spread to other parts of the body)?

Press Y/N or 1/2